[關(guān)鍵詞]
[摘要]
目的 探討關(guān)節(jié)克痹丸聯(lián)合依托考昔片治療膝骨關(guān)節(jié)炎的臨床療效。方法 選取唐山市人民醫(yī)院在2023年2月—2025年1月收治的92例膝骨關(guān)節(jié)炎患者。92例患者按隨機數(shù)字表法分為對照組和治療組,每組46例。對照組口服依托考昔片,1次/d,1片/次。治療組在對照組基礎(chǔ)上口服關(guān)節(jié)克痹丸,2次/d,8丸/次。兩組完成3個月治療。比較兩組的治療效果、晨僵時間、疼痛程度、關(guān)節(jié)功能、生活質(zhì)量和血清指標。結(jié)果 對照組總有效率為82.61%,治療組總有效率為95.65%,組間比較差異顯著(P<0.05)。治療后,兩組的晨僵時間、數(shù)字疼痛強度量表(NRS)評分、Lequesne指數(shù)評分降低(P<0.05);治療組的晨僵時間、NRS評分、Lequesne指數(shù)評分低于對照組(P<0.05)。兩組治療后SF-36評分均升高(P<0.05),且治療組SF-36評分比對照組高(P<0.05)。兩組治療后的血清趨化因子配體2(CCL2)、高遷移率族蛋白B1(HMGB1)、組織蛋白酶D(CATD)水平顯著降低(P<0.05);治療組治療后的血清CCL2、HMGB1、CATD水平低于對照組(P<0.05)。結(jié)論 關(guān)節(jié)克痹丸聯(lián)合依托考昔片可提高膝骨關(guān)節(jié)炎的臨床療效,減輕膝關(guān)節(jié)晨僵和疼痛程度,改善膝關(guān)節(jié)功能,提高生活質(zhì)量,降低炎癥反應(yīng)。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Guanjie Kebi Pills combined with Etoricoxib Tablets in treatment of knee osteoarthritis.Methods 92 Patients with knee osteoarthritis admitted to Tangshan People's Hospital from February 2023 to January 2025 were selected, and were divided into control group and treatment group using random number table method, with 46 cases in each group. The control group took oral Etoricoxib Tablets, once daily, 1 tablets/time. The treatment group were orally administered with Guanjie Kebi Pills on the basis of the control group, twice daily, 8 pills per time. Two groups completed 3 months of treatment. The treatment efficacy, morning stiffness time, pain level, joint function, quality of life, and serum indicators between two groups of patients were compared.Results The total effective rate of the control group was 82.61%, while the total effective rate of the treatment group was 95.65%, with significant differences between the groups (P < 0.05). After treatment, the morning stiffness time, NRS scores, and Lequesne index scores of both groups were decreased (P < 0.05), and the morning stiffness time, NRS scores, and Lequesne index scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the SF-36 scores of both groups were decreased (P < 0.05), and the SF-36 scores of the treatment group was higher than those in the control group (P < 0.05). The serum levels of chemokine ligand 2 (CCL2), high mobility group protein B1 (HMGB1), and cathepsin D (CATD)were significantly decreased after treatment in both groups (P < 0.05), and the levels of CCL2, HMGB1, and CATD in the treatment group were lower than those in the control group after treatment (P < 0.05).Conclusion The combination of Guanjie Kebi Pills and Etoricoxib Tablets can improve the clinical efficacy of knee osteoarthritis, alleviate morning stiffness and pain in the knee joint, improve knee joint function, enhance quality of life, and reduce inflammatory reactions.
[中圖分類號]
R977
[基金項目]
河北省衛(wèi)生健康委科研基金項目(20201524)